Furthermore, a decrease in platelet reactivity has been shown with PCSK9 inhibition treatment,44 suggesting that PCSK9 inhibitors as well as aspirin may reduce the risk of cardiovascular disease by counteracting the enhancing effects of PCSK9 on platelet reactivity. Here, PCSK9 is linked to cardiovascular disorder.